Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6814487 | 0.95 | MMP13 (0.56) | CNR2MMP13LMNAALDH1A1KDM4E | |
| SCHEMBL6700076 | 0.90 | MMP13 (0.57) | MMP13PIK3CD | |
| SCHEMBL6703316 | 0.84 | CNR2 (0.52) | CNR2MMP13LMNAALDH1A1KDM4E | |
| SCHEMBL6698574 | 0.84 | LMNA (0.48) | MMP13LMNAALDH1A1KDM4EHPGD | |
| SCHEMBL6703507 | 0.81 | MMP13 (0.56) | CNR2MMP13LMNAALDH1A1KDM4E | |
| SCHEMBL6698919 | 0.79 | CNR2 (0.53) | CNR2MMP13LMNAALDH1A1KDM4E | |
| SCHEMBL6702032 | 0.71 | MMP13 (0.66) | MMP13 | |
| SCHEMBL6704257 | 0.71 | MMP13 (0.57) | MMP13POLBCTDSP1KMT2A | |
| SCHEMBL6705173 | 0.70 | MMP13 (0.52) | MMP13LMNAALDH1A1KDM4EHPGD | |
| SCHEMBL6701275 | 0.70 | IDO1 (0.48) | CNR2MMP13HPGDPOLBIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | CNR2 3386/4885MMP13 13/4885LMNA 2847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.